Show simple item record

dc.contributor.authorTiruvoipati, Ravindranath
dc.contributor.authorBuscher, Hergen
dc.contributor.authorWinearls, James
dc.contributor.authorBreeding, Jeff
dc.contributor.authorGhosh, Debasish
dc.contributor.authorChaterjee, Shimonti
dc.contributor.authorBraun, Gary
dc.contributor.authorPaul, Eldho
dc.contributor.authorFraser, John F
dc.contributor.authorBotha, John
dc.date.accessioned2021-09-20T04:49:00Z
dc.date.available2021-09-20T04:49:00Z
dc.date.issued2016
dc.identifier.issn1441-2772
dc.identifier.urihttp://hdl.handle.net/10072/408103
dc.description.abstractBackground: Recent advances in the technology of extracorporeal respiratory assist systems have led to a renewed interest in extracorporeal carbon dioxide removal (ECCOR). The Hemolung is a new, low-flow, venovenous, minimally invasive, partial ECCOR device that has recently been introduced to clinical practice to aid in avoiding invasive ventilation or to facilitate lung-protective ventilation. Objective: We report our early experience on use, efficacy and safety of the Hemolung in three Australian intensive care units. Methods: Retrospective review of all patients with acute or acute-on-chronic respiratory failure (due to chronic obstructive pulmonary disease [COPD] with severe hypercapnic respiratory failure when non-invasive ventilation failed; acute respiratory distress syndrome; COPD; or asthma when lung-protective ventilation was not feasible due to hypercapnia) for whom the Hemolung was used. Results: Fifteen patients were treated with ECCOR. In four out of five patients, the aim of avoiding intubation was achieved. In the remaining 10 patients, the strategy of instituting lung-protective ventilation was successful. The median duration for ECCOR was 5 days (interquartile range, 3-7 days). The pH and PCO2 improved significantly within 6 hours of instituting ECCOR, in conjunction with a significant reduction in minute ventilation. The CO2 clearance was 90–100 mL/min. A total of 93% of patients survived to weaning from ECCOR, 73% survived to ICU discharge and 67% survived to hospital discharge. Conclusion: Our data shows that ECCOR was safe and effective in this cohort. Further experience is vital to identify the patients who may benefit most from this promising therapy.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherCollege of Intensive Care Medicine
dc.publisher.urihttps://search-informit-org.libraryproxy.griffith.edu.au/doi/10.3316/INFORMIT.515405062198667
dc.relation.ispartofpagefrom261
dc.relation.ispartofpageto269
dc.relation.ispartofissue4
dc.relation.ispartofjournalCritical Care and Resuscitation
dc.relation.ispartofvolume18
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchNursing
dc.subject.fieldofresearchcode3202
dc.subject.fieldofresearchcode4205
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsCritical Care Medicine
dc.subject.keywordsGeneral & Internal Medicine
dc.subject.keywordsPOSITIVE-PRESSURE VENTILATION
dc.titleEarly experience of a new extracorporeal carbon dioxide removal device for acute hypercapnic respiratory failure
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationTiruvoipati, R; Buscher, H; Winearls, J; Breeding, J; Ghosh, D; Chaterjee, S; Braun, G; Paul, E; Fraser, JF; Botha, J, Early experience of a new extracorporeal carbon dioxide removal device for acute hypercapnic respiratory failure, Critical Care and Resuscitation, 2016, 18 (4), pp. 261-269
dc.date.updated2021-09-20T04:47:32Z
gro.hasfulltextNo Full Text
gro.griffith.authorFraser, John F.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record